Patents by Inventor Pierre Tiollais

Pierre Tiollais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5510472
    Abstract: Human interferon-beta.sub.2.sbsb.A and interferon-beta.sub.2.sbsb.B are produced in purified form by recombinant DNA techniques. Two separate human genes have been identified which code for the production of IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B, respectively. The sequence of IFN-.beta..sub.2.sbsb.A cDNA is established. These genes and cDNA have been cloned into mammalian cells with an SV40 early promoter sequence and such genomic clones are capable of producing IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B. The antiviral activity of such recombinant IFN-.beta..sub.2.sbsb.A and IFN-.beta..sub.2.sbsb.B is demonstrated as well as other biological activity identifying them as human interferons.
    Type: Grant
    Filed: May 15, 1992
    Date of Patent: April 23, 1996
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Michel Revel, Pierre Tiollais
  • Patent number: 5468609
    Abstract: The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.
    Type: Grant
    Filed: September 28, 1982
    Date of Patent: November 21, 1995
    Assignee: Yeda Research & Development Co. Ltd.
    Inventors: Michel Revel, Pierre Tiollais
  • Patent number: 5468608
    Abstract: The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.
    Type: Grant
    Filed: September 28, 1982
    Date of Patent: November 21, 1995
    Assignee: Yeda Research & Development Co., Ltd.
    Inventors: Michel Revel, Pierre Tiollais
  • Patent number: 5468617
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: November 21, 1995
    Inventors: Hughes Blaudin De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5468607
    Abstract: The present invention relates to a process to isolate genetic material (DNA) containing the nucleotide sequence coding for interferon in human fibroblastic cells which comprises cultivating cells producing interferon when exposed to an inducer of interferon, exposing same to such inducer, extracting messenger RNA from said induced cells, purifying the interferon messenger RNA, transcribing the messenger RNA into DNA and cloning the DNA in a suitable vector. Preferred cells are human diploid foreskin cells. The invention further relates to a process for engineering a bacterial strain to produce interferon polypeptide which comprises introducing a cloned interferon DNA into a suitable vector-carrier. A preferred vector-carrier is E. coli. The invention also relates to the mRNA of human interferon in highly purified form, to the mRNA of human interferon in .beta.1 highly purified form, to the mRNA of human interferon in .beta.
    Type: Grant
    Filed: November 20, 1980
    Date of Patent: November 21, 1995
    Assignee: Yeda Research & Development Co. Ltd.
    Inventors: Michel Revel, Pierre Tiollais
  • Patent number: 5376530
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: July 22, 1993
    Date of Patent: December 27, 1994
    Assignee: Institut Pasteur
    Inventors: Hughes B. De The, Agnes Marchio, Pierre Tiollais, Anne DeJean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5324513
    Abstract: The invention concerns a composition useful for the manufacture of vaccines containing particles having the immunogenic properties characteristic of the antigen HBsAg, these particles being more particularly characterized by the fact that the said particles equally contain a receptor for polymerized human albumin. They are obtained by transformation of human or animal cells by a vector containing a DNA sequence coding for the S and pre-S regions of a genome of viral hepatitis B, this DNA sequence being placed under the direct control of a promoter permitting the effective transcription of the said sequence in the human or animal cells transformable by the said vector.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: June 28, 1994
    Assignees: Institut Pasteur, Institut National De La Sante Et De La Rocherche Medicale, Centre National De La Recherche Scientifique
    Inventors: Eliane Sobczak, Yves Malpiece, deceased, Marie-Louise Michel, Pierre Tiollais, Rolf E. Streeck
  • Patent number: 5317090
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences. The hap protein is a retinoic acid (RA) receptor identified as RAR-.beta.. The RAR-.beta.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: May 31, 1994
    Assignee: Institut Pasteur
    Inventors: Hughes Blaudin De The, Agnes Marchio, Pierre Tiollais, Anne Dejean, Nigel Brand, Martin Petkovich, Andree Krust, Pierre Chambon
  • Patent number: 5314808
    Abstract: Method for the production of antigens vaccinating against the virus of B viral hepatitis. It consists of transforming a cell culture with a vector, more particularly a plasmid, itself containing an insertion sequence including itself at least the part of the viral DNA coding for the immunogen protein, capable of inducing in vivo antibody production active with respect to the whole virus, as well as the viral promoter under the control of which the transcription and translation of the above-said part of viral DNA is normally carried out, in particular in a host infected with the corresponding virus.
    Type: Grant
    Filed: April 5, 1983
    Date of Patent: May 24, 1994
    Assignees: Institut Pasteur, Institut Nationale de la Sante et de la Recherche Medicale
    Inventors: Pierre Tiollais, Charles Chany, Marie-Francoise Dubois, Christine Pourcel, Anne Louise
  • Patent number: 5223606
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.
    Type: Grant
    Filed: December 17, 1987
    Date of Patent: June 29, 1993
    Assignee: Institut Pasteur
    Inventors: Hughes Blaudin de The, Agnes Marchio, Pierre Tiollais, Anne DeJean
  • Patent number: 5149781
    Abstract: A previously isolated hepatitis B virus (HBV) integration in a 147 bp cellular DNA fragment linked to hepatocellular carcinoma (HCC) was used as a probe to clone the corresponding complementary DNA from a human liver cDNA library. Nucleotide sequence analysis revealed that the overall structure of the cellular gene, which has been named hap, is similar to that of the DNA-binding hormone receptors. Six out of seven hepatoma and hepatoma-derived cell-lines express a 2.5 kb hap mRNA species which is undetectable in normal adult and fetal livers, but present in all non-hepatic tissues analyzed. Low stringency hybridization experiments revealed the existence of hap related genes in the human genome. The cloned DNA sequence is useful in the preparation of pure hap protein and as a probe in the detection and isolation of complementary DNA and RNA sequences.
    Type: Grant
    Filed: June 20, 1988
    Date of Patent: September 22, 1992
    Assignee: Institut Pasteur
    Inventors: Hugues Blaudin de THE, Agnes Marchio, Pierre Tiollais, Anne Dejean
  • Patent number: 4428941
    Abstract: Nucleic acid of reduced size and vector containing said nucleotidic sequence of which DNA codes an immunogenic peptidic sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 3A. Application to the production by cloning in a bacterium of an immunogenic protein immunizing against hepatitis B, or application to the obtention of probes for the diagnosis of the presence of Dane particles in a serum.
    Type: Grant
    Filed: April 30, 1981
    Date of Patent: January 31, 1984
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Francis Galibert, Pierre Tiollais, Patrick Charnay
  • Patent number: 4371625
    Abstract: The invention pertains to a set of vectors (or of DNA fragments to be inserted in a vector) which distinguish from one another in that, taking into account one vector in which the number of pairs of bases between the reading initiation point of the vector and a point corresponding to the first pair of bases of a recognition site corresponding to a predetermined restriction enzyme, the two other vectors comprise between the corresponding points additional groups of pairs of bases comprising respectively two pairs of bases on the one hand and either one or four pairs of bases on the other hand, plus possibly whole numbers of triplets. On inserting a determined DNA fragment of which the expression is sought in bacteria in the three vectors, the reading of said DNA fragment will occur in phase as concerns one of the so modified vectors after transfection of bacteria therewith.
    Type: Grant
    Filed: November 13, 1979
    Date of Patent: February 1, 1983
    Assignees: Institut Pasteur, Inst. Nat'l de la Sante et Recherche
    Inventor: Pierre Tiollais
  • Patent number: RE34705
    Abstract: Nucleic acid of reduced size and vector containing said nucleotidic sequence of which DNA codes an immunogenic peptidic sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 3A. Application to the production by cloning in a bacterium of an immunogenic protein immunizing against hepatitis B, or application to the obtention of probes for the diagnosis of the presence of Dane particles in a serum.
    Type: Grant
    Filed: January 14, 1991
    Date of Patent: August 23, 1994
    Assignees: Institut Pasteur, Institut National de la Sante et de la Recherche Medicale
    Inventors: Francis Galibert, Pierre Tiollais, Patrick Charnay